A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
      Google Scholar   
Citation:
Cancer Chemother Pharmacol vol 63 (5) 859-64
Year:
2009
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
CA33601, CA11789, CA02599, CA47577, CA47555, CA32291, CA41287, CA03927, U10 CA033601, CA60138, CA 33601, CA77440, CA74811, CA47559, CA45418, CA77658, CA31983, CA31946  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
CALGB-19804
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Aged, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Female, Harringtonines, Humans, Infusions, Intravenous, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Male, Middle Aged, Neoplasm Staging, Palliative Care, Prognosis, Prospective Studies, Risk Factors, Survival Rate, Time Factors, Treatment Outcome